A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

Completed · Phase 1

Conditions studied: Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic

In brief

The purpose of the study is to determine the dose limiting toxicities and maximum tolerated dose of motexafin gadolinium when administered with docetaxel and cisplatin in patients with Non-small Cell Lung Cancer. A cycle consists of 3 weeks. During week 1, patients receive MGd, docetaxel, and cisplatin treatment followed by 2 weeks without treatment. Eligible patients will receive 1 or 2 doses of MGd, depending on cohort, and a single dose of docetaxel and cisplatin at 75 mg/m² during the first week of each cycle. Additionally, tumor response will be evaluated at the end of even numbered cycles (2, 4, and 6). Patients may stay on the study a maximum of 6 cycles.

Key facts

Study ID

NCT00102505

Run by

Pharmacyclics LLC.

People needed

36

Starts

2004-11-01

Last updated by the study team

2009-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years old
• ECOG score of 0, 1, or 2
• Histologically confirmed diagnosis of non-small cell lung cancer

You may not qualify if…

• Laboratory values demonstrating inadequate function of the following:
• Bone marrow
• Kidneys
• Liver
• and
• Peripheral neuropathy Grade 2 or higher
• Greater than 2 prior chemotherapy regimens

Where it is running

• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.